Eric Shinohara, MD, MSCI

home / authors / eric-shinohara-md-msci

Articles

Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate Cancer

Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate Cancer

Eric Shinohara, MD, MSCI
May 8th 2020

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

Read More

Dr. Shinohara on Radiation Therapy Considerations in Prostate Cancer

Dr. Shinohara on Radiation Therapy Considerations in Prostate Cancer

Eric Shinohara, MD, MSCI
April 28th 2020

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

Read More

Dr. Shinohara on Toxicities of Stereotactic Body Radiotherapy in Prostate Cancer

Dr. Shinohara on Toxicities of Stereotactic Body Radiotherapy in Prostate Cancer

Eric Shinohara, MD, MSCI
January 30th 2020

Eric Shinohara, MD, MSCI, discusses the toxicities associated with stereotactic body radiotherapy in prostate cancer.

Read More

Dr. Shinohara on the Future of Radiation and Surgery in Prostate Cancer

Dr. Shinohara on the Future of Radiation and Surgery in Prostate Cancer

Eric Shinohara, MD, MSCI
January 25th 2020

Eric Shinohara, MD, MSCI, discusses the future of stereotactic body radiation and surgery in prostate cancer.

Read More

Dr. Shinohara on Stereotactic Body Radiotherapy to Treat Prostate Cancer

Dr. Shinohara on Stereotactic Body Radiotherapy to Treat Prostate Cancer

Eric Shinohara, MD, MSCI
November 26th 2019

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need